-
Mashup Score: 38Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 - 2 month(s) ago
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3 - 2 month(s) ago
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) improves outcomes for patients with acute myeloid leukemia (AML) harboring an internal tandem duplication mutation of FLT3 (FLT3-ITD) AML. These patients are routinely treated with a FLT3 inhibitor after HCT, but there is limited evidence to support this. Accordingly, we conducted a randomized trial of post-HCT maintenance with the FLT3 inhibitor gilteritinib (ClinicalTrials.gov identifier: NCT02997202) to determine if all such patients benefit or if detection of measurable residual disease (MRD) could identify those who might benefit. METHODS Adults with FLT3-ITD AML in first remission underwent HCT and were randomly assigned to placebo or 120 mg once daily gilteritinib for 24 months after HCT. The primary end point was relapse-free survival (RFS). Secondary end points included overall survival (OS) and the effect of MRD pre- and post-HCT on RFS and OS. RESULTS Three hundred fifty-six participants were randomly assigned post-
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy - 2 month(s) ago
Chimeric antigen receptor T cells (CAR-T) targeting the B-cell maturation antigen (BCMA) have transformed the care of patients with relapsed/refractory (R/R) multiple myeloma (MM). Outcomes reported in pivotal studies have led to the approval of 2 anti-BCMA CAR-T therapy products, idecabtagene vicluecel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which have demonstrated significant improvements over prior standard of care in patients with triple-class exposed (TCE) RRMM [1–4]. The response rates to these therapies range between 73% and 98% [1,2,5].
Source: www.astctjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD - 2 month(s) ago
T-reg graft plus single-agent prophylaxis is preferred over T-reg graft alone for the prevention of acute GVHD.
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6
We observed a significant survival advantage in older subjects with higher-risk MDS who have a matched donor identified and underwent reduced-intensity HCT, when compared with those without a donor. HCT should be included as an integral part of MDS management plans in fit older adults with higher-ri …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27
Bone Marrow Transplantation – Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study - 3 month(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19Incidence and Risk Factors of Early Onset VOD/SOS Differ in Younger vs Older Adults After Stem Cell Transplantation - 3 month(s) ago
Key Points. Young adults (18-25 years) are a distinct population with high rates of VOD.Disease-related factors predict for VOD in young adults (18-25 years) an
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 73
Extending the duration of letermovir prophylaxis to 200 days following HSCT is efficacious and safe in reducing the incidence of late clinically significant cytomegalovirus infection in patients at risk.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 68
Extending the duration of letermovir prophylaxis to 200 days following HSCT is efficacious and safe in reducing the incidence of late clinically significant cytomegalovirus infection in patients at risk.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
Gilteritinib vs. placebo as Post-Transplant Maintenance for AML With FLT3-ITD. N=356. RFS was higher for patients with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib @MediHumdani @BMTCTN @JCO_ASCO #bmtsm https://t.co/IWP2dL3AN3